BRAF and neoplasm: Although this patient never received a MEK inhibitor to target MAPK pathway upregulation associated with the possible BRAF V600E mutation, trametinib vs. PGBM on OBSCs killed about one-third of the tumor at the highest dose (DSS = 16), correlating slightly better with the negative DNA mutation analysis of the tumor rather than the patchy positive IHC, although the term “patchy” is certainly qualitative.